Dova Pharmaceuticals Inc

Dova Pharmaceuticals — Investor Presentation (October 2018)

32 slides from Dova Pharmaceuticals's investor presentation, Oct 2, 2018

  1. Slide 1: Disclaimer

    Disclaimer Certain information contained in this presentation relates to or is based on studies, surveys and other data obtained from third-party sources and Dova’s own internal estimates and research. While Dova believes these sources to be reliable as of the date of this presentation, it has not i

  2. Slide 2: Key Business Highlights At-A-Glance

    Key Business Highlights At-A-Glance treatment of thrombocytopenia (i.e., low platelet counts) patients with chronic liver disease scheduled to undergo a procedure Thrombocytopenic Purpura (ITP) 3 $134.7M cash and equivalents on hand (as of June 30, 2018) $12M used to fund Clinical and Commercial ope

  3. Slide 3: DOPTELET has multiple avenues for growth

    DOPTELET has multiple avenues for growth PST: Pre-Surgery Thrombocytopenia ITP: Immune Thrombocytopenia Purpura CIT: Cancer Induced Thrombocytopenia * Anticipated year of approval / unblinding

  4. Slide 4: May 21st, 2018: DOPTELET receives FDA approval

    May 21st, 2018: DOPTELET receives FDA approval THE FIRST THERAPEUTIC AGENT FOR THE TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE PRIOR TO PLANNED PROCEDURES 5

  5. Slide 5: DOPTELET Indication

    DOPTELET Indication Indication: DOPTELET (avatrombopag) is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS DOPTELET is a thro

  6. Slide 6: ~1MM patients with Chronic Liver Disease and associated thrombocytopenia

    There are ~1MM patients with Chronic Liver Disease (CLD) and associated thrombocytopenia Mild 170,000 Moderate 70,000 Severe 20,000 treme 7 Source: Poordad et. al., Aliment Pharmacol Ther, 26 (Suppl 1), 5-11, 2007, Giannini et al, Alimentary Pharm and Therapeutics, 24, 1055-1064, 2006 PATIENTS >75,0

  7. Slide 7: Thrombocytopenic CLD patients who had procedure-related bleeding

    Thrombocytopenic CLD patients who had procedure-related bleeding Patients with Moderate or Severe Thrombocytopenia have a 30% risk of Procedure-Related Bleeding 50% 40% 30% 20% 10% 0% <75,000/µL >75,000/µL Platelet count Number and proportion of thrombocytopenic patients who had procedure-related bl

  8. Slide 8: Platelet transfusion issues

    Platelet transfusions issues are associated with clinically significant RISK OF ANTIBODY DEVELOPMENT SHORT DURATION OF EFFECT AND LIMITED SUPPLY 3 1 • May lead to refractoriness in up to ~50% of patients • • Short shelf life of platelets (5 days) Transfusion must be given same day as procedure RISK

  9. Slide 9: Approval driven by two randomized controlled trials (n=435)

    Approval was driven by consistent results from two randomized controlled trials (n=435) PROPORTION OF PATIENTS WHO DID NOT REQUIRE PLATELET TRANSFUSION OR ANY RESCUE PROCEDURE FOR BLEEDING ADAPT-1 / ADAPT-2 (<40K / µL) ADAPT-1 / ADAPT-2 (40K / µL to <50K / µL) ADAPT-1 / ADAPT-2 (<35K / µL) P < 0.000

  10. Slide 10: Encouraging early launch metrics

    Encouraging early launch metrics Q2 Launch Metrics Q3 Launch Metrics Q4 Launch Metrics # of unique prescribers 148* % of adjudicated Rx’s approved by payers 81% Average time to payer approval 6.9 days % of target prescribers contacted 62%: average of 3.1 times Change in channel inventory levels N/A

  11. Slide 11: Unique prescribers of DOPTELET

    Unique prescribers of DOPTELET* Unique Prescribers of DOPTELET* 61% 39% Non-Gastroenterologist Gastroenterologist *number of Unique Prescribers that had prescribed DOPTELET to a patient as of August 8, 2018 = 148 12

  12. Slide 12: Market Segmentation

    Market Segmentation Centers (LTC) w/o LTC Large Gastro. Group Independent Setting 13 Low Potential Medium Potential High Potential Academic Setting Academic Centers Liver Transplant Small GI PracticesPractices Community

  13. Slide 13: Co-promotion agreement with Salix Pharmaceuticals

    September 27, 2018: Dova announces co-promotion agreement with Salix Pharmaceuticals Unique Prescribers of DOPTELET* 100 sales representatives focused on large GI Group Practices 4-year term Salix receives commission (mid 20% - mid 30%) on Net Sales generated by GI Training commences October 9th Sel

  14. Slide 14: DOPTELET launch has commenced

    DOPTELET launch has commenced! Specialty Pharmacy Distributors National Account Manager Team Managed Care Organizations 15

  15. Slide 15: Our campaign has evolved

    Our campaign has evolved increase to focus on platelet count May 21, 2018 DOPTELET Receives FDA Approval Sept. 27, 2018 Co-Promote with Salix Announced TARGET A MEANINGFUL RESPONSE 16

  16. Slide 16: Usage of DOPTELET expected to increase in next months

    Usage of DOPTELET expected to increase in next 6 months Initial reviews of DOPTELET are generally POSITIVE. Nearly 2/3 of physicians anticipate INCREASING usage in next 6 months % who anticipate using more DOPTELET in the Next 6 Months* (5-7 on a 7 point scale) Top unaided reasons for expected incre

  17. Slide 17: DOPTELET: potential to address various types of thrombocytopenia

    DOPTELET: potential to address thrombocytopenia various types of PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL STATUS Thrombocytopenia in CLD patients scheduled to undergo a procedure LAUNCHED Chronic Immune Thrombocytopenic Purpura (ITP) sNDA submitted on August 30, 2018 Trial Initiated / Sites Ac

  18. Slide 18: DOPTELET: potential to address various types of thrombocytopenia

    DOPTELET: Potential to Thrombocytopenia Address Various types of PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL STATUS Thrombocytopenia in CLD patients scheduled to undergo a procedure LAUNCHED Chronic Immune Thrombocytopenic Purpura (ITP) sNDA submitted on August 30, 2018 Trial Initiated / Sites Ac

  19. Slide 19: DOPTELET has been studied in ITP patients

    DOPTELET has been studied in 128 ITP patients with average patient exposure of PHASE 7 months 3 STUDY 16 DC’ED 10 DC’ED 20 Jurczak W, et al. Br J Haematol. 2018. Published Online, https://doi.org/10.1111/bjh.15573 22 COMPLETE 1 COMPLETE 32 AVATROMBOPAG 17 PLACEBO 49 RANDOMIZED

  20. Slide 20: Phase 3 study of DOPTELET in ITP: platelet response

    Phase weeks 3 study of DOPTELET in ITP: cumulative number of of platelet response > 50K / µL P < 0.0001 67% 0 WEEKS PLACEBO N=32 AVATROMBOPAG N=32 21 Jurczak W, et al. Br J Haematol. 2018. Published Online, https://doi.org/10.1111/bjh.15573 WEEKS 12 WEEKS

  21. Slide 21: Avatrombopag Phase 3 ITP efficacy data: median platelet count

    Avatrombopag Phase 3 ITP efficacy data: median platelet count over time Avatrombopag maintained the target platelet count (50 to <150×109/L) over the 6-month treatment period 200 Concomitant ITP Med Reduction Titration Maintenance 180 160 140 120 Target Range: 50-150 x 109/L 100 80 60 40 20 0 0 1 2

  22. Slide 22: Chronic ITP is a $1.5 Billion Market; DOPTELET well-differentiated

    The Chronic ITP market is a $1.5 Billion Market. If Approved by FDA, we believe DOPTELET is Well-Differentiated HEPATOTOXICITY DOSING FOOD EFFECT CONVENIENT ADMINISTRATION WITH FOOD NO HEPATOTOXICTY ORAL DOSING PROMACTA MAY INCREASE THE RISK OF SEVERE AND POTENTIALLY LIFE-THREATENING HEPATOTOXICITY

  23. Slide 23: Demonstrated favorability of DOPTELET in Chronic ITP

    Demonstrated favorability of DOPTELET could result in a potentially significant market share in Chronic ITP Favors DOPTELET Favors Competitor Equals More favorable Less favorable 24 Source: Triangle Insights Group, results of n = 100 quantitative responses. Conducted: March 2018 Administration: Diet

  24. Slide 24: Anticipated ITP regulatory timeline

    Anticipated ITP regulatory timeline August 30 sNDA submission for the treatment of ITP 2018 2019 October 29 June 30 sNDA filing date (Day 60) PDUFA date (assuming sNDA is filed by FDA) 25

  25. Slide 25: DOPTELET: potential to address various types of thrombocytopenia

    DOPTELET: potential to address thrombocytopenia various types of PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL STATUS Thrombocytopenia in CLD patients scheduled to undergo a procedure LAUNCHED Chronic Immune Thrombocytopenic Purpura (ITP) sNDA submitted on August 30, 2018 Trial Initiated / Sites Ac

  26. Slide 26: Potential fit for DOPTELET in CIT standard of care

    Potential fit for DOPTELET in CIT standard of care DOPTELET has the potential to address a significant unmet medical need for patients with CIT Dose Reduction 1 Cycle Delay / Cancellation 2 Platelet Transfusion 3 4 27 * Zhang X, et al. Cochrane Database Syst Rev. 2017;11:CD02035. Hitron A, et al. J

  27. Slide 27: Chemotherapy Induced Thrombocytopenia (CIT) study design

    Chemotherapy Induced Thrombocytopenia (CIT) STUDY DESIGN Phase 3 randomized, double-blind, placebo-controlled study of the efficacy and safety of oral avatrombopag in subjects with active non-hematological cancers (i.e., ovarian, NSCLC, bladder) who develop CIT (platelet count <50K / µL in the previ

  28. Slide 28: Several important milestones over the next 18-24 months

    Several important potential commercial and clinical milestones over the next 18-24 months October 29 sNDA filing date (Day 60) August 30 sNDA submission for the treatment of ITP Q2/Q3, 2019 DOPTELET Approval in Europe 2018 2019 2020 May 21 mid-2020 CIT study unblinded June 30 FDA approval of DOPTELE

  29. Slide 29: Strong Balance Sheet

    Strong Balance Sheet $134.7MILLION CASH AND EQUIVALENTS AS OF 6/30/18 $20 MILLION NOTE PAYABLE $12 MILLION OPERATING CASH BURN IN Q2 2018 TO FUND CLINICAL AND COMMERCIAL ACTIVITY. BURN ANTICIPATED TO CONTINUE TO INCREASE WITH FULL COMMERCIAL ACTIVITIES 30

  30. Slide 30: Near-Term revenue with strong pipeline for continued growth

    Near-Term revenue with strong pipeline for continued growth LARGE US MARKET OPPORTUNITY $800 Million in CLD indication $850 Million in ITP ($1.5 billion global) $1.7 Billion in follow-on acute indications (CIT and PST) ROBUST PIPELINE STRONG CASH POSITION 2018 JUNE LAUNCH FAVORABLE IP Strong start t

  31. Slide 31: Near-Term revenue with strong pipeline for continued growth

    Near-Term revenue with strong pipeline for continued growth OOO) @GO) H LARGEUS i 2018 JUNE MARKET bene FAVORABLE IP era LAUNCH OPPORTUNITY | i * Strong start to 1 + $800 Million in CLD. a sNDA for ITP ($1.5 * Composition of matter |* $134.7 Million launch i indication i billion global patents expir

  32. Slide 32: Dova Pharmaceuticals

    Dova PHARMACEUTICALS

Dova Pharmaceuticals — Investor Presentation (October 2018) on 6ix